Table 2.
Comparisons of OMA associated symptoms at baseline (TB) and after 12 months (T12), in dienogest (D), estrogen-progestogens (EPs), and no-treatment (NoT) groups.
| D (n = 62) | EPs (n = 38) | NoT (n = 42) | ||||
|---|---|---|---|---|---|---|
| TB | T12 | TB | T12 | TB | T12 | |
| Dysmenorrhea | 49 (79%) | 18 (29%) | 29 (76%) | 22 (42%) | 20 (47%) | 21 (50%) |
| VAS for dysmenorrhea | 5.59 (4.1) | 1.41 (2.7) | 5.44 (3.1) | 3.15 (3.3) | 5.19 (3.4) | 5.28 (3.5) |
| Dyspareunia | 32 (51%) | 17 (27%) | 22 (57%) | 17(44%) | 15 (35%) | 14(33%) |
| VAS for dyspareunia | 3.38 (3.8) | 1.87 (2.76) | 4.10 (3.5) | 2.55 (3.2) | 2.95 (3.2) | 3.2 (3.3) |
| CPP | 26 (41%) | 16 (25%) | 16 (42%) | 9 (21%) | 16 (38%) | 16 (38%) |
| VAS for CPP | 1.98 (2.7) | 1.09 (2.0) | 1.57 (2.5) | 1.02 (2.1) | 1.95 (2.9) | 1.85 (2.7) |
VAS: visual analog scale; CPP: chronic pelvic pain.
Data are reported as n (rate) and score (standard deviation).